Interim Report January - June 2002

BIOINVENT INTERIM REPORT 1 JANUARY - 30 JUNE 2002 q BioInvent acquires the rights to develop and commercialise a new type of drug against HIV. q New collaboration agreements with CellControl Laboratories AG and Pharmacia Diagnostics AB will result in high capacity utilisation in the production facility. q In a directed new share issue Oxford GlycoSciences Plc subscribed for 1,331,251 new shares at a price of SEK 39.06 per share. The payment injected funds of SEK 52 million into BioInvent. q Net revenue for January - June 2002 increased to SEK 40.3 million (28.6). q Cash flow from current operations and investment activity, January - June 2002 amounted to SEK 4.1 million (-22,4). Liquid funds at end of period: SEK 394.8 million Loss after net financial items January - June 2002 amounted to SEK -23.9 million (-22.5). Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)708 97 82 13 Jonas Källmén, CFO, +46 (0)708 77 48 07 The report is also available at: www.bioinvent.com BioInvent International AB (publ.) Company reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00580/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00580/wkr0002.pdf The full report

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

Subscribe